Affimed(AFMDQ)
$0.00-0.00 (-99.97%)
AFMDQ
Affimed stock drug pipeline
$0.00
At close:-0.00 (-99.97%)
Want to see AFMDQ full AI Analyst Report?
Affimed (AFMDQ) Drug Pipeline
841 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Afm13, Cyclophosphamide, Fludarabine, Interleukin-2, Ab-101 | Peripheral T Cell Lymphoma, Relapsed Or Refractory Hodgkin Lymphoma | Phase II | Terminated | Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL | May 19, 2023 | ― |
| Afm28 | Acute Myeloid Leukemia | Phase I | Terminated | First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Mar 22, 2023 | ― |
| Afm24, Atezolizumab 840 Mg In 14 Ml Injection | Advanced Solid Tumor | phase1AndPhase2 | Terminated | Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers | Oct 01, 2021 | ― |
| 14 Mg Afm24, 40 Mg Afm24, 80 Mg Afm24, 160 Mg Afm24, 320 Mg Afm24, 480 Mg Afm24, 720 Mg Afm24 | Advanced Solid Tumor | phase1AndPhase2 | Terminated | Study to Assess AFM24 in Advanced Solid Cancers | Feb 03, 2020 | ― |
| Afm13 | Peripheral T Cell Lymphoma, Transformed Mycosis Fungoides | Phase II | Completed | Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides | Sep 20, 2019 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Afm13, Cyclophosphamide, Fludarabine, Interleukin-2, Ab-101 | Phase II | Peripheral T Cell Lymphoma, Relapsed Or Refractory Hodgkin Lymphoma | Terminated | Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL | May 19, 2023 | ― |
| Afm28 | Phase I | Acute Myeloid Leukemia | Terminated | First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Mar 22, 2023 | ― |
| Afm24, Atezolizumab 840 Mg In 14 Ml Injection | phase1AndPhase2 | Advanced Solid Tumor | Terminated | Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers | Oct 01, 2021 | ― |
| 14 Mg Afm24, 40 Mg Afm24, 80 Mg Afm24, 160 Mg Afm24, 320 Mg Afm24, 480 Mg Afm24, 720 Mg Afm24 | phase1AndPhase2 | Advanced Solid Tumor | Terminated | Study to Assess AFM24 in Advanced Solid Cancers | Feb 03, 2020 | ― |
| Afm13 | Phase II | Peripheral T Cell Lymphoma, Transformed Mycosis Fungoides | Completed | Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides | Sep 20, 2019 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Affimed N.V. (AFMDQ) have in its pipeline
Affimed AFMDQ is currently developing the following drugs: Afm13, Cyclophosphamide, Fludarabine, Interleukin-2, Ab-101, Afm28, Afm24, Atezolizumab 840 Mg In 14 Ml Injection, 14 Mg Afm24, 40 Mg Afm24, 80 Mg Afm24, 160 Mg Afm24, 320 Mg Afm24, 480 Mg Afm24, 720 Mg Afm24, Afm13. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
